JAKi therapy was associated with a significantly lower risk of uveitis in patients with elevated CRP (≥3 mg/L; HR, 0.50; 95% CI, 0.26–0.96) and elevated ESR (≥20 mm/h; HR, 0.41; 95% CI, 0.19–0.87). Here, CRP is linked to uveitis.